
News|Articles|May 1, 2002
Health systems/plans share common coverage vision for Clarinex, OTC Claritin
Last month the FDA's Nonprescription Drugs Advisory Committee unanimously supported loratadine's (Claritin, Schering-Plough) switch from prescription to over-the-counter status for treatment of chronic idiopathic urticaria, moving the drug one step closer to full OTC status (see significant event timeline in sidebar).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk
3
Intervention boosts connected insulin pen adoption among minorities with Type 1 diabetes
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























